•   Friday, 5 September
  •   Saturday, 6 September
  •   Sunday, 7 September
General Session
State-of-the-Art Lecture
Special Lecture
Industry Symposium
TIME Friday, 5 September
 11.30 – 12.30 Biocompatibles Symposium
The histological and clinical impact of the treatment of HCC patients eligible for surgery with intra arterial, doxorubicin Drug-Eluting Beads*

Lunch provided
12.30 – 12.45 Session Break
12.45 – 13.00 Opening Ceremony
13.00 – 15.00

Risk factors in the pathogenesis of HCC
Chairs: Nelson Fausto (USA); Irene Ng (China)

  • Identification of potential therapeutic targets in pre-clinical models of HCC
    Speaker: Nelson Fausto (USA)
  • Pathogenesis of HCV-induced HCC
    Speaker: Jake Liang (USA)
  • Pathogenesis of HBV-induced HCC
    Speaker: Patrizia Paterlini-Bréchot (France)
  • Chronic inflammation and altered SAMe methabolism in – NASH and alcohol-induced HCC
    Speaker: José M. Mato (Spain)
15.00 – 15.30 Coffee and Networking Break
15.30 – 16.15 Clinical Lecture: Evidence-based outcomes in cancer research and HCC
Chair: Scott Friedman (USA)
Speaker: Barnett Kramer (USA)
16.15 – 16.30 Session Break
16.30 – 18.00 General Session 1: Treatment of HCC –Surgery and local ablation
Chairs: Jacques Belghiti (France)
Michael Abecassis, Chicago (USA)
O-001   Outcome following salvage liver transplant for recurrent hepatocellular carcinoma after resection: analysis of the OPTN database
Presenting author: Francis YaoO-002   Partial liver resection for HCC in patients with good liver function can challenge liver transplantation
Presenting author: Jacques BelghitiO-003   Outcome after curative resection for huge (10cm or more) hepatocellular carcinoma and prognostic significance of gross classification
Presenting author: Dai Hoon HanO-004   Interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis – wonder or woe?  
Presenting author: Stefan BreitensteinO-005   Predictive factors of distant recurrence and survival in 203 patients with cirrhosis child pugh a and hepatocellular carcinoma HCC (≤ 5cm) treated by radiofrequency ablation (RFA)  
Presenting author: Gisèle G. N. NkontchouO-006   Treatment of malignant liver tumors with percutaneous microwave ablation: experience with complications in 1136 patients
Presenting author: Ping Liang
18.00 – 18.15 Session Break
18.15 – 19.15 Bayer Schering Pharma Symposium
Forging partnerships in the management of Hepatocellular Carcinoma:
multidisciplinary strategies to provide continuity of care*
19.15 – 20.00 Welcome Reception

TIME Saturday, 6 September
08.00 – 09.00 Sirtex Symposium
Expanding treatment options in HCC through Radioembolisation/SIRT*
09.00 – 09.30 IARC perspective: New concepts in the epidemiology of HCC
Chair: Hashem El-Serag (USA)
Speaker: Paolo Boffetta (France)
09.30 – 09.45 Session Break
09.45 – 11.15 General Session 2: Molecular pathogenesis (genomics)
Chairs: Xin Wei Wang (USA)
Peter Galle (Germany)
O-007   Hepatocellular carcinoma with progenitor cell features: clinical and biological characterization
Presenting author: Pippa Newell

O-008   Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma
Presenting author: Yujin Hoshida

O-009   Transcriptional regulation of micro-RNAs highly expressed in human HCCs
Presenting author: Natalia Pediconi

O-010   miRNA-based molecular classification of hepatocellular carcinoma
Presenting author: Sara Toffanin

O-011   Molecular profiles in human nonalcoholic steatohepatitis (NASH) – related hepatocellular carcinoma (HCC) assessed by whole genome bioarray hybridization
Presenting author: Flair José Carrilho

O-012   In vivo reptin silencing blocks hepatocellular carcinoma progression
Presenting author: Jean Rosenbaum11.15 – 11.45 Coffee and Networking Break11.45 – 12.30 Translational Lecture: Molecular pathology and HCC: from cell of origin to diagnosis
Chair: Masamichi Kojiro (Japan)
Speaker: Pierre Bedossa (France)
12.30 – 14.15 Poster Session and Lunch14.15 – 14.45 Forty years of research in HCC in South Africa
Chair: Morris Sherman (Canada)
Speaker: Michael Kew (South Africa)
14.45 – 16.15 General Session 3: Clinical trials in molecular therapies
Chairs: Didier Samuel (France)
Al Benson (USA)
O-013   Phase 2 open-label study of brivanib alaninate in patients with hepatocellular carcinoma
Presenting author: Joong-Won Park

O-014   Determining the impact of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ecog performance status (PS) on sorafenib safety and efficacy in patients with advanced hepatocellular carcinoma (HCC): sharp trial subset analyses
Presenting author: Jean-Luc Raoul

O-015   Randomized, phase I and pharmacokinetic (PK) study of RAD001, a mTOR inhibitor, in patients (PTS) with advanced hepatocellular carcinoma (HCC)
Presenting author: Li-Tzong Chen

O-016   Small molecule antagonists of beta-catenin/Tcf4 complex inhibit the growth of HCC cells in vitro and in vivo  
Presenting author: Wei Wei

O-017   Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): analysis of correlations with outcome and tumor imaging parameters  Presenting author: Sandrine J. Faivre

O-018   A phase I clinical trial of prodrug-activating gene therapy for patients with hepatocellular carcinoma
Presenting author: Bruno Sangro16.15 – 16.45 Coffee and Networking Break16.45 – 18.15 General Session 4: Signaling and novel targets
Chairs: Gregory J. Gores (USA)
Sheng-Long Ye (P.R. China)
O-019   Transforming growth factor-beta gene expression signature predicts clinical outcome in cancer  
Presenting author: Cedric COULOUARN

O-020   A gene signature enables to discriminate vascular invasion in patients with hepatocellular carcinoma
Presenting author: Beatriz Minguez

O-021   Identification of potential driver genes in hepatocellular carcinoma: mechanistic and clinical implications
Presenting author: Hyun Goo Woo

O-022   Bolstering hepatic cancer stem cells by Wnt/beta-catenin signaling  
Presenting author: Xin Wei Wang

O-023   lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma
Presenting author: Lun-Xiu Qin

O-024   Specific oncogenic pathways are activated in the different hepatocellular adenoma subtypes of tumors  
Presenting author: Sandra Rebouissou18.15 – 18.45 Emerging molecules in HCC
Chair: Adrian M. Di Bisceglie (USA)
Speaker: Melanie Thomas (USA)
18:45 – 21:15ILCA-Workshop:
Liver transplantation in HCC
Entering the era beyond Milan and UCSF criteria in OLT
Building the future in solid ground
Pierre-Alain Clavien, Switzerland
Vincenzo Mazzaferro, Italy

Introduction: Goals, controversial data, goal of the workshop
Speaker: Pierre-Alain Clavien, Switzerland

Topic 1: Extension on what basis?

  • Morphological parameters of HCC (size, number and volume of the tumor)
    Chairs: Rafik M Ghobrial, USA, Myron Schwartz,USA
  • UCSF / UCLA Criteria
    Speaker: Francis Yao, USA
  • Oriental Criteria
    Speaker: Masatoshi Makuuchi, Japan
  • Volume of the tumor
    Speaker: Sven Jonas, Germany
  • Biological markers and surrogates implying tumor sampling
    Chairs: Snorri Thorgeirsson, USA, Kim Olthoff, USA
  • Vascular invasion, Grading
    Speaker: Eberhard Renner, Canada
  • DNA ploidy implying serum markers, PIVKA
    Speaker: Hiroto Egawa, Japan

Topic 2: Precising end-points in the extension process
Chairs: Josep Llovet, Spain/USA, Stefan Breitenstein, Switzerland

  • Limitation of technology and modern approach of pre-transplant staging
    Speaker: Riccardo Lencioni, Italy
  • New model of prognostication: the “Metroticket caldulator”
    Speaker: Vincenzo Mazzaferro, Italy

Topic 3: Should extended criteria be different between cadaveric and living donation?
Jacques Belghiti, France and Jordi Bruix,  Spain/USA

  • YES
    Speaker: Zakiyah Kadry, USA
  • NO
    Speaker: Michael Abecassis, USA

Topic 4: Influence of pre-transplant downstaging on post-transplant outcome and prognostication
Pierre-Alain Clavien, Switzerland, Didier Samuel, France

  • Pre-transplant downstaging
    Speaker: Beat Müllhaupt, Switzerland

Vincenzo Mazzaferro, Italy

TIME Sunday, 7 September
08.30 – 10.00 General Session 5: Epidemiology and molecular diagnosis
Chairs: Elizabeth M. Brunt (USA)
Young Nyun Park (Korea)
O-025   Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease – a national cohort study, 1978-2003
Presenting author: Rune Erichsen

O-026   Burden of hepatocellular cancer in a national sample of patients with chronic hepatitis C
Presenting author: Fasiha Kanwal

O-027   Occurrence of hepatitis C-related hepatocellular carcinoma (HCC) in the absence of cirrhosis: results from the HALT-C trial
Presenting author: Adrian M. Di Bisceglie

O-028   Hepatocellular carcinoma associated to chronic hepatitis delta
Presenting author: Raffaella Romeo

O-029   Telomere shortening, micronuclei, and inactivation of p21 during human multistep hepatocarcinogenesis
Presenting author: Young Nyun Park

O-030   Hepatocytic differentiation in cholangiocellular carcinoma suggesting hepatic progenitor cell origin
Presenting author: Mina Komuta10.00 – 10.30 Coffee and Networking Break10.30 – 12.30

Loco-regional treatments in HCC
Chairs: Luigi Bolondi (Italy)
Byung Ihn Choi (Korea)

  • Local ablation: state-of-the art
    Riccardo Lencioni (Italy)
  • Chemoembolization: Eastern perspective
    Kenichi Takayasu (Japan)
  • Internal radiation: review of phase II data
    Riad Salem (USA)
  • Overview of evidence-based diagnosis and loco-regional management of HCC
    Andrew Burroughs (UK)

12.30 – 14.00 General Session 6 : Medical treatments
Chairs: Andrew Zhu (USA)
Kwang-Hyub Han (Korea)
O-031   A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma
Presenting author: Melanie B. Thomas


O-032   Efficacy and safety of sorafenib in asian patients with advanced hepatocellular carcinoma  
Presenting author: Ann-Lii Cheng

O-033   Actual survival following chemoembolization for hepatocellular carcinoma in a US center: correlation with prognostic systems
Presenting author: Michael C. Soulen

O-034   Radiologic-pathologic correlation of treated HCC tumors with Y90 microspheres
Presenting author: Laura Kulik

O-035   Radioembolization with therasphere yttrium-90 glass microspheres for advanced hepatocellular carcinoma: a European pilot phase II study
Presenting author: Philip Hilgard

O-036   RE-188 Lipiodol therapy of hepatocellular carcinoma: results of a multinational study  
Presenting author: Ajit K. Padhy14.00 Closing Remarks